Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.2K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

660
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
660
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

855
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
855
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

335
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
335

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interventions to Optimize Medication Management in Older Adults: An Umbrella Review of Systematic Reviews.

Journal of the American Geriatrics Society·2026
Same author

Efficacy of Adjunct PRObiotics as Compared to the Standard Care in Moderate Unipolar Depression Among Geriatric Patients: A Randomized Double-Blind Placebo-Controlled Pilot Multi-Center Trial (PRODG).

Journal of the American Geriatrics Society·2026
Same author

LaminA/C-dependent cellular senescence signaling promotes skeletal muscle atrophy and abnormalities in Parkinson's disease.

Cell death & disease·2026
Same author

Real-time monitoring of glycocarrier formation unravels cryptic details in glycosyl transfer.

RSC chemical biology·2026
Same author

The skeletal muscle slow myosin heavy chain regulates mammalian metabolic homeostasis through the NRF2 pathway.

Science advances·2026
Same author

CRISP: Enhancing ASE Workflows With Advanced Molecular Simulation Post-Processing.

Journal of computational chemistry·2026
Same journal

Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.

Therapeutic advances in psychopharmacology·2026
Same journal

Patient-centred education for ketamine and esketamine therapies in mood disorders.

Therapeutic advances in psychopharmacology·2026
Same journal

Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel.

Therapeutic advances in psychopharmacology·2026
Same journal

Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review.

Therapeutic advances in psychopharmacology·2026
Same journal

Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.

Therapeutic advances in psychopharmacology·2026
Same journal

Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.

Therapeutic advances in psychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K

Brexpiprazole: so far so good.

Saibal Das1, Preeti Barnwal2, Blessed Winston A3

  • 1Department of Pharmacology, Christian Medical College, Vellore, 632002, India.

Therapeutic Advances in Psychopharmacology
|February 26, 2016
PubMed
Summary
This summary is machine-generated.

Brexpiprazole, a new antipsychotic, shows promise for schizophrenia and depression treatment. It offers improved efficacy and a better safety profile compared to older medications, with fewer side effects.

Keywords:
antipsychoticbrexpiprazolemajor depressive disorderschizophrenia

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Related Experiment Videos

Last Updated: Mar 25, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Schizophrenia and major depressive disorder (MDD) require effective treatments with favorable safety profiles.
  • Existing antipsychotics often present significant adverse effects, limiting their use.
  • Brexpiprazole is a novel agent targeting specific neurotransmitter receptors.

Purpose of the Study:

  • To review the pharmacological profile of brexpiprazole.
  • To assess its efficacy and safety in treating schizophrenia and MDD.
  • To compare brexpiprazole with aripiprazole and chlorpromazine.

Main Methods:

  • Analysis of pharmacological data including receptor affinity and functional activity.
  • Review of data from key clinical trials (VECTOR and BEACON).
  • Comparative analysis of product characteristics from the FDA database.

Main Results:

  • Brexpiprazole exhibits a unique receptor binding profile, including partial agonism at 5-HT1A and D2 receptors and antagonism at 5-HT2A receptors.
  • Demonstrates potential for improving cognitive function, sleep, and affective states in schizophrenia and MDD.
  • Exhibits a lower risk of adverse effects like extrapyramidal symptoms and metabolic complications compared to other antipsychotics.

Conclusions:

  • Brexpiprazole presents a favorable antipsychotic profile for schizophrenia monotherapy.
  • It can serve as an effective adjunct treatment for major depressive disorder.
  • Its distinct pharmacological actions may offer an improved therapeutic option with reduced side effect burden.